Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment

Arthritis and Rheumatism

Volumn 60, Issue 6, 2009, Pages 1825-1830

  Kim, Susan ^a   El Hallak, Moussa ^a   Dedeoglu, Fatma ^a   Zurakowski, David ^a   Fuhlbrigge, Robert C ^a   Sundel, Robert P ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; PREDNISONE; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ACUTE PSYCHOSIS; ADOLESCENT; ARTICLE; BODY HEIGHT; CALCIFICATION; CALCINOSIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MUSCLE STRENGTH; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MUSCLE WEAKNESS; MUSCLE, SKELETAL; OUTCOME ASSESSMENT (HEALTH CARE); REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 66449110796     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24571     Document Type: Article

References (25)

1. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr 1964;64:101-131
2. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005;52:3570-3578 (Pubitemid 41612226)
3. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000;27:2498-2503
4. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-549 (Pubitemid 30394944)
5. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983;103:882-888 (Pubitemid 14204178)
6. Cimaz R. Osteoporosis in childhood rheumatic diseases: prevention and therapy. Best Pract Res Clin Rheumatol 2002;16:397-409. (Pubitemid 36526651)
7. Pachman LM, Maryjowski MC. Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 1984;10:95-115. (Pubitemid 14141235)
8. Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho Mde S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002;60:889-899 (Pubitemid 35439728)
9. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008;87:70-86.
10. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-511
11. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-347
12. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:7-15. (Pubitemid 36286124)
13. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52:2607-2615
14. Machin D, Cheung YB, Parmar M. Survival analysis: a practical approach. 2nd ed. New York: Wiley; 2006.
15. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974 (Pubitemid 14272804)
16. Holland JF. Hopes for tomorrow versus realities of today: therapy and prognosis in acute lymphocytic leukemia of childhood. Pediatrics 1970;45:191-193
17. Baum E, Sather H, Nachman J, Seinfeld J, Krivit W, Leikin S, et al. Relapse rates following cessation of chemotherapy during complete remission of acute lymphocytic leukemia. Med Pediatr Oncol 1979;7:25-34.
18. Donadieu J, Auclerc MF, Baruchel A, Leblanc T, Landman-Parker J, Perel Y, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group. Br J Haematol 1998;102:729-739
19. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
20. Progress against childhood cancer: the Pediatric Oncology Group experience. Pediatrics 1992;89(4 Pt 1):597-600.
21. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001;7:899-905. (Pubitemid 32756426)
22. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95. (Pubitemid 37323232)
23. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-898 (Pubitemid 34303799)
24. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008;59:222-226
25. National Cancer Institute. Common toxicity criteria. URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf.